Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte announced that the Prosigna breast cancer test has been recommended for use in all Swedish healthcare regions without legal restrictions

Click to view original post